<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5bc23817-cddb-4448-bbf3-969db4cee912"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PHENYLEPHRINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for PHENYLEPHRINE HYDROCHLORIDE INJECTION <br/>PHENYLEPHRINE HYDROCHLORIDE injection, for intravenous use<br/>Initial U.S. Approval:1954</title>
   <effectiveTime value="20250305"/>
   <setId root="170e63f1-23f4-4839-ab89-b81832d94a56"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079947873" root="1.3.6.1.4.1.519.1"/>
            <name>Somerset Therapeutics, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="079947873" root="1.3.6.1.4.1.519.1"/>
                  <name>Somerset Therapeutics, LLC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="677236695" root="1.3.6.1.4.1.519.1"/>
                        <name>Somerset Therapeutics Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-591" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-591" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-591" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-591" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="74cdb45c-c04b-40a2-9a9d-0a7bf49e1370"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250305"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-591" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phenylephrine Hydrochloride</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phenylephrine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="04JA59TNSJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENYLEPHRINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1WS297W6MV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENYLEPHRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="9" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70069-591-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43165" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AMPULE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70069-591-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250304"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA215617" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID96">
               <id root="566d0620-3d50-434c-94e0-c813faae632c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID97">Phenylephrine hydrochloride injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. </paragraph>
               </text>
               <effectiveTime value="20210323"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID99">Phenylephrine Hydrochloride Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.(<linkHtml href="#ID96">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID100">
               <id root="d7549c4f-ca45-4ee7-979d-aae3896d2249"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250207"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID110" styleCode="Disc">
                           <item>Phenylephrine hydrochloride injection 500 mcg/5 mL (100 mcg/mL) MUST NOT BE DILUTED before administration as an intravenous bolus. It is supplied as a READY-TO-USE formulation.</item>
                        </list>
                        <paragraph ID="ID111">
                           <content styleCode="underline">Dosing for treatment of hypotension during anesthesia </content>
                        </paragraph>
                        <list listType="unordered" ID="ID112" styleCode="Disc">
                           <item>Bolus intravenous injection: Initial dose is 40 mcg to 100 mcg. Additional boluses up to 200 mcg may be administered every 1 to 2 minutes as needed.</item>
                           <item>Adjust the dose according to the pressor response (i.e., titrate to effect).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID101">
                     <id root="04d02a54-5983-49c8-a49b-6ba12781db99"/>
                     <title>2.1 General Dosage and Administration Instructions</title>
                     <text>
                        <paragraph ID="ID102">During Phenylephrine Hydrochloride Injection administration: </paragraph>
                        <list listType="unordered" ID="ID103" styleCode="Disc">
                           <item>Correct intravascular volume depletion.</item>
                           <item>Correct acidosis. Acidosis may reduce the effectiveness of      phenylephrine.</item>
                        </list>
                        <paragraph ID="ID104">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. Discard any unused portion.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Administration Instructions for Phenylephrine Hydrochloride Injection, 500 mcg/5 mL (100 mcg/mL):</content>
                        </paragraph>
                        <paragraph>Phenylephrine Hydrochloride Injection, 500 mcg/5 mL (100 mcg/mL) MUST<content styleCode="underline"> NOT BE DILUTED </content>before administration as an intravenous bolus. It is supplied as <content styleCode="underline">READY-TO-USE </content>formulation.</paragraph>
                     </text>
                     <effectiveTime value="20250207"/>
                  </section>
               </component>
               <component>
                  <section ID="ID105">
                     <id root="6516730e-5cc2-40c5-b436-625d346340ef"/>
                     <title>2.2 Dosing for Treatment of Hypotension during Anesthesia</title>
                     <text>
                        <paragraph ID="ID106">The following are the recommended dosages for the treatment of hypotension during anesthesia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Phenylephrine Hydrochloride Injection, 500 mcg/5 mL (100 mcg/mL):                         </content>
                        </paragraph>
                        <list listType="unordered" ID="ID107" styleCode="Disc">
                           <item>The recommended initial dose is 40 to 100 mcg administered by      intravenous bolus. Additional boluses may be administered every 1-2      minutes as needed; not to exceed a total dosage of 200 mcg.</item>
                           <item>Adjust dosage according to the blood pressure goal.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID113">
               <id root="17259a90-ee5f-4d2c-a426-60953bf7594a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID114">
                     <content styleCode="underline">Ampule</content>
                  </paragraph>
                  <paragraph>Phenylephrine hydrochloride injection USP, 500 mcg/5 mL (100 mcg/mL), for intravenous use, is a clear and colorless solution available in a type I clear ampule white snap off and blue band, 5 mL single-dose ampule containing 5 mL of solution for injection, corresponding to 0.5 mg of phenylephrine hydrochloride per ampule, (equivalent to 0.41 mg of phenylephrine base). </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID117" styleCode="Disc">
                           <item>Phenylephrine hydrochloride injection 500 mcg/5 mL (100 mcg/mL): 5 mL single-dose ampule containing 5 mL of solution for injection corresponding to 0.5 mg of phenylephrine hydrochloride per ampule.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID118">
               <id root="dac92059-556e-4021-b09c-2248c43288ee"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID119">None (<linkHtml href="#ID118">4</linkHtml>)</paragraph>
               </text>
               <effectiveTime value="20201211"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID121">None (<linkHtml href="#ID118">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID122">
               <id root="efdcce93-5baa-4b8f-9eb5-cb1107fdc951"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210323"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID138">
                           <content styleCode="underline">Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension</content>: Phenylephrine Hydrochloride Injection can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. (<linkHtml href="#ID123">5.1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Peripheral and Visceral Ischemia</content>: Phenylephrine Hydrochloride Injection can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs. (<linkHtml href="#ID125">5.2</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Skin and Subcutaneous Necrosis</content>: Extravasation during intravenous administration may cause necrosis or sloughing of tissue. (<linkHtml href="#ID127">5.3</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Bradycardia: </content>Phenylephrine Hydrochloride Injection can cause severe bradycardia and decreased cardiac output.  (<linkHtml href="#ID129">5.4</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID123">
                     <id root="7fc789aa-dec3-40ce-acc5-aaa8251206ab"/>
                     <title>5.1 Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension</title>
                     <text>
                        <paragraph ID="ID124">Because of its increasing blood pressure effects, phenylephrine hydrochloride injection can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. </paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID125">
                     <id root="ba8ffae6-197d-44d2-bf7c-48a3d419336a"/>
                     <title>5.2 Peripheral and Visceral Ischemia</title>
                     <text>
                        <paragraph ID="ID126">Phenylephrine hydrochloride injection can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease. </paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID127">
                     <id root="4409f311-afa2-4d50-8b86-598ba38a06f9"/>
                     <title>5.3 Skin and Subcutaneous Necrosis</title>
                     <text>
                        <paragraph ID="ID128">Extravasation of phenylephrine hydrochloride injection can cause necrosis or sloughing of tissue. Avoid extravasation by checking infusion site for free flow.</paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID129">
                     <id root="9493b80a-871f-4241-a253-ddb03c7a407e"/>
                     <title>5.4 Bradycardia</title>
                     <text>
                        <paragraph ID="ID130">Phenylephrine hydrochloride injection can cause severe bradycardia and decreased cardiac output.</paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID131">
                     <id root="6073b6ff-35a0-4a72-a5f9-adad0c968034"/>
                     <title>5.5 Renal Toxicity</title>
                     <text>
                        <paragraph ID="ID132">Phenylephrine hydrochloride injection can increase the need for renal replacement therapy in patients with septic shock. Monitor renal function. </paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID133">
                     <id root="4b7025fc-abba-4e05-8044-5734fcc73f52"/>
                     <title>5.6 Risk of Augmented Pressor Affect in Patients with Autonomic Dysfunction</title>
                     <text>
                        <paragraph ID="ID134">The increasing blood pressure response to adrenergic drugs, including phenylephrine hydrochloride injection, can be increased in patients with autonomic dysfunction, as may occur with spinal cord injuries. </paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID135">
                     <id root="323412ca-ad7a-4445-bb3a-3257a3b48156"/>
                     <title>5.7 Pressor Effect with Concomitant Oxytocic Drugs</title>
                     <text>
                        <paragraph ID="ID136">Oxytocic drugs potentiate the increasing blood pressure effect of sympathomimetic pressor amines including phenylephrine hydrochloride injection <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID122">7.1</linkHtml>)]</content>, with the potential for hemorrhagic stroke. </paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID139">
               <id root="978ff275-a9d2-4904-a9f6-1e8fed81611a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID140">Adverse reactions to phenylephrine hydrochloride injection are primarily attributable to excessive pharmacologic activity. Adverse reactions reported in published clinical studies, observational trials, and case reports of phenylephrine hydrochloride injection are listed below by body system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiac disorders</content>: Reflex bradycardia, lowered cardiac output, ischemia, hypertension, arrhythmias</paragraph>
                  <paragraph>
                     <content styleCode="underline">Gastrointestinal disorders</content>: Epigastric pain, vomiting, nausea</paragraph>
                  <paragraph>
                     <content styleCode="underline">Nervous system disorders</content>: Headache, blurred vision, neck pain, tremors </paragraph>
                  <paragraph>
                     <content styleCode="underline">Vascular disorders</content>: Hypertensive crisis </paragraph>
                  <paragraph>
                     <content styleCode="underline">Respiratory, Thoracic and Mediastinal Disorders</content>: Dyspnea </paragraph>
                  <paragraph>
                     <content styleCode="underline">Skin and subcutaneous tissue disorders</content>: Pruritis</paragraph>
               </text>
               <effectiveTime value="20210323"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID142">Most common adverse reactions during treatment: nausea, vomiting, and headache. (<linkHtml href="#ID139">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch</content>
                              </content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID143">
               <id root="1c3de75d-e474-4bb8-814b-3383528a923d"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240818"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID151">
                           <content styleCode="underline">Agonistic Effects (increase in Phenylephrine Hydrochloride Injection blood pressure effect)</content> can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (<linkHtml href="#ID143">7.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antagonistic Effects (decrease in Phenylephrine Hydrochloride Injection blood pressure effect)</content> can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α-and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (<linkHtml href="#ID143">7.2</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID144">
                     <id root="81e0c898-0aad-4c75-a458-b1a2ab37af33"/>
                     <title>7.1 Interactions that Augment the Pressor Effect</title>
                     <text>
                        <paragraph ID="ID145">The increasing blood pressure effect of phenylephrine hydrochloride injection is <content styleCode="underline">increased </content>in patients receiving: </paragraph>
                        <list listType="unordered" ID="ID146" styleCode="Disc">
                           <item>Monoamine oxidase inhibitors (MAOI)</item>
                           <item>Oxytocin and oxytocic drugs</item>
                           <item>Tricyclic antidepressants</item>
                           <item>Angiotensin, aldosterone</item>
                           <item>Atropine</item>
                           <item>Steroids, such as hydrocortisone</item>
                           <item>Norepinephrine transporter      inhibitors, such as atomoxetine</item>
                           <item>Ergot alkaloids, such as methylergonovine      maleate</item>
                        </list>
                     </text>
                     <effectiveTime value="20240818"/>
                  </section>
               </component>
               <component>
                  <section ID="ID147">
                     <id root="2354645e-fc86-4c95-ba38-6adccf0cf203"/>
                     <title>7.2 Interactions that Antagonize the Pressor Effect</title>
                     <text>
                        <paragraph ID="ID148">The increasing blood pressure effect of phenylephrine hydrochloride injection is <content styleCode="underline">decreased </content>in patients receiving: </paragraph>
                        <list listType="unordered" ID="ID149" styleCode="Disc">
                           <item>α-adrenergic antagonists</item>
                           <item>Phosphodiesterase Type 5 inhibitors</item>
                           <item>Mixed α-and β-receptor      antagonists</item>
                           <item>Calcium channel blockers, such as      nifedipine</item>
                           <item>Benzodiazepines</item>
                           <item>ACE inhibitors</item>
                           <item>Centrally acting sympatholytic      agents, such as reserpine, guanfacine</item>
                        </list>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID152">
               <id root="54a7f48e-2838-42b2-8813-2ab04164a415"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250217"/>
               <component>
                  <section ID="ID153">
                     <id root="605301d1-31b0-4b21-8923-95d6ea575e0b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID154">
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Data from randomized controlled trials and meta-analyses with phenylephrine hydrochloride injection use in pregnant women during caesarean section have not established a drug-associated risk of major birth defects and miscarriage. These studies have not identified an adverse effect on maternal outcomes or infant Apgar scores <content styleCode="italics">[<linkHtml href="#ID152">see Data</linkHtml>]</content>. There are no data on the use of phenylephrine during the first or second trimester. In animal reproduction and development studies in normotensive animals, evidence of fetal malformations was noted when phenylephrine was administered during organogenesis via a 1-hour infusion at 1.2 times the human daily dose (HDD) of 10 mg/60 kg/day. Decreased pup weights were noted in offspring of pregnant rats treated with 2.9 times the HDD <content styleCode="italics">[See Data]. </content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryofetal Risk </content>
                        </paragraph>
                        <paragraph>Untreated hypotension associated with spinal anesthesia for cesarean section is associated with an increase in maternal nausea and vomiting. A sustained decrease in uterine blood flow due to maternal hypotension may result in fetal bradycardia and acidosis. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>Published randomized controlled trials over several decades, which compared the use of phenylephrine injection to other similar agents in pregnant women during cesarean section, have not identified adverse maternal or infant outcomes. At recommended doses, phenylephrine does not appear to affect fetal heart rate or fetal heart variability to a significant degree. </paragraph>
                        <paragraph>There are no studies on the safety of phenylephrine injection exposure during the period of organogenesis, and therefore, it is not possible to draw any conclusions on the risk of birth defects following exposure to phenylephrine injection during pregnancy. In addition, there are no data on the risk of miscarriage following fetal exposure to phenylephrine injection. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>No clear malformations or fetal toxicity were reported when normotensive pregnant rabbits were treated with phenylephrine via continuous intravenous infusion over 1 hour (0.5 mg/kg/day; approximately equivalent to a HDD based on body surface area) from Gestation Day 7 to 19. At this dose, which demonstrated no maternal toxicity, there was evidence of developmental delay (altered ossification of sternebra). </paragraph>
                        <paragraph>In a non-GLP dose range-finding study in normotensive pregnant rabbits, fetal lethality and cranial, paw, and limb malformations were noted following treatment with 1.2 mg/kg/day of phenylephrine via continuous intravenous infusion over 1 hour (2.3-times the HDD). This dose was clearly maternally toxic (increased mortality and significant body weight loss). An increase in the incidence of limb malformation (hyperextension of the forepaw) coincident with high fetal mortality was noted in a single litter at 0.6 mg/kg/day (1.2-times the HDD) in the absence of maternal toxicity.</paragraph>
                        <paragraph>No malformations or embryo-fetal toxicity were reported when normotensive pregnant rats were treated with up to 3 mg/kg/day phenylephrine via continuous intravenous infusion over 1 hour (2.9-times the HDD) from Gestation Day 6 to 17. This dose was associated with some maternal toxicity (decreased food consumption and body weights). </paragraph>
                        <paragraph>Decreased pup weights were reported in a pre-and postnatal development toxicity study in which normotensive pregnant rats were administered phenylephrine via continuous intravenous infusion over 1 hour (0.3, 1.0, or 3.0 mg/kg/day; 0.29, 1, or 2.9 times the HDD) from Gestation Day 6 through Lactation Day 21). No adverse effects on growth and development (learning and memory, sexual development, and fertility) were noted in the offspring of pregnant rats at any dose tested. Maternal toxicities (mortality late in gestation and during lactation period, decreased food consumption and body weight) occurred at 1 and 3 mg/kg/day of phenylephrine (equivalent to and 2.9 times the HDD, respectively).</paragraph>
                     </text>
                     <effectiveTime value="20201211"/>
                  </section>
               </component>
               <component>
                  <section ID="ID155">
                     <id root="f29e0c85-2dd8-4b36-b140-fd30fe8980aa"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID156">
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There are no data on the presence of phenylephrine hydrochloride injection or its metabolite in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for phenylephrine hydrochloride injection and any potential adverse effects on the breastfed infant from phenylephrine hydrochloride injection or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20250217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID157">
                     <id root="9e69cc58-06d7-4487-97c7-8dec0b0ec845"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID158">Safety and effectiveness in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20201211"/>
                  </section>
               </component>
               <component>
                  <section ID="ID159">
                     <id root="8644e341-035d-4474-8513-81605ef0b1c4"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID160">Clinical studies of phenylephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </paragraph>
                     </text>
                     <effectiveTime value="20201211"/>
                  </section>
               </component>
               <component>
                  <section ID="ID161">
                     <id root="e3421368-c323-4bc6-83d4-63326e147330"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID162">In patients with liver cirrhosis [Child Pugh Class B and Class C], dose-response data indicate decreased responsiveness to phenylephrine. Start dosing in the recommended dose range but more phenylephrine may be needed in this population.</paragraph>
                     </text>
                     <effectiveTime value="20250217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID163">
                     <id root="29a466fc-6c0b-4306-a128-f644b008ff2d"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID164">In patients with end stage renal disease (ESRD), dose-response data indicate increased responsiveness to phenylephrine. Consider starting at the lower end of the recommended dose range, and adjusting dose based on the target blood pressure goal. </paragraph>
                     </text>
                     <effectiveTime value="20250217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID165">
               <id root="9ed60e37-6cff-4c3f-b2e2-27a90ebea443"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID166">Overdose of phenylephrine hydrochloride injection (phenylephrine hydrochloride) can cause a rapid rise in blood pressure. Symptoms of overdose include headache, vomiting, hypertension, reflex bradycardia, a sensation of fullness in the head, tingling of the extremities, and cardiac arrhythmias including ventricular extrasystoles and ventricular tachycardia. </paragraph>
               </text>
               <effectiveTime value="20210323"/>
            </section>
         </component>
         <component>
            <section ID="ID167">
               <id root="0ce18a67-aa62-49f8-9bea-04255d640e1b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID168">Phenylephrine is an alpha-1 adrenergic receptor agonist. The chemical name of phenylephrine hydrochloride is (-)-<content styleCode="italics">m</content>-hydroxy-α-[(methylamino) methyl] benzyl alcohol hydrochloride, its molecular formula is C<sub>9</sub>H<sub>13</sub>NO<sub>2</sub> · HCl (Molecular Weight: 203.67 g/mol) and its structural formula is depicted below:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID170">Phenylephrine hydrochloride is soluble in water and ethanol, and insoluble in chloroform and ethyl ether. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Phenylephrine hydrochloride injection, 500 mcg/5 mL (100 mcg/mL):</content>
                  </paragraph>
                  <paragraph>Phenylephrine hydrochloride injection, 500 mcg/5 mL (100 mcg/mL), is a sterile, nonpyrogenic, clear and colorless solution for intravenous use. It MUST NOT BE DILUTED before administration as an intravenous bolus.</paragraph>
                  <paragraph>Each mL contains: phenylephrine hydrochloride 100 mcg (equivalent to 80 mcg of phenylephrine base), sodium chloride 9.0 mg, in water for injection. The pH is adjusted with hydrochloric acid if necessary. The pH range is 3.0 to 5.0. </paragraph>
               </text>
               <effectiveTime value="20250217"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="5bc23817-cddb-4448-bbf3-969db4cee912-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID171">
               <id root="8911995b-1b5a-4809-8a68-a7f141f3c4f9"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20201211"/>
               <component>
                  <section ID="ID172">
                     <id root="44ded838-1cec-46b0-8ca2-78f05088053a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID173">Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist. </paragraph>
                     </text>
                     <effectiveTime value="20201211"/>
                  </section>
               </component>
               <component>
                  <section ID="ID174">
                     <id root="2ed636a7-ef78-4631-b823-a3a175ef1cb2"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID175">Interaction of phenylephrine with α-1 adrenergic receptors on vascular smooth muscle cells causes activation of the cells and results in vasoconstriction. Following phenylephrine hydrochloride intravenous administration, increases in systolic and diastolic blood pressures, mean arterial blood pressure, and total peripheral vascular resistance are observed. The onset of blood pressure increase following an intravenous bolus phenylephrine hydrochloride administration is rapid, typically within minutes. As blood pressure increases following intravenous administration, vagal activity also increases, resulting in reflex bradycardia. Phenylephrine has activity on most vascular beds, including renal, pulmonary, and splanchnic arteries. </paragraph>
                     </text>
                     <effectiveTime value="20201211"/>
                  </section>
               </component>
               <component>
                  <section ID="ID176">
                     <id root="29e042b0-c5f4-41e6-90ce-596132fb244b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID177">Following an intravenous infusion of phenylephrine hydrochloride, the observed effective half-life was approximately 5 minutes. The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues. The average total serum clearance is approximately 2100 mL/min. The observed phenylephrine plasma terminal elimination half-life was 2.5 hours. </paragraph>
                        <paragraph>Phenylephrine is metabolized primarily by monoamine oxidase and sulfotransferase. After intravenous administration of radiolabeled phenylephrine, approximately 80% of the total dose was eliminated within first 12 h; and approximately 86% of the total dose was recovered in the urine within 48 h. </paragraph>
                        <paragraph>The excreted unchanged parent drug was 16% of the total dose in the urine at 48 h post intravenous administration. There are two major metabolites, with approximately 57 and 8% of the total dose excreted as m-hydroxymandelic acid and sulfate conjugates, respectively. The metabolites are considered not pharmacologically active.</paragraph>
                     </text>
                     <effectiveTime value="20201211"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID178">
               <id root="8e17404e-f528-437c-8c59-f7ec5605ca6d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210323"/>
               <component>
                  <section ID="ID179">
                     <id root="7c7cad9a-d257-439a-b81c-7da8f2600035"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID180">
                           <content styleCode="underline">Carcinogenesis</content>: Long-term animal studies that evaluated the carcinogenic potential of orally administered phenylephrine hydrochloride in F344/N rats and B6C3F<sub>1</sub> mice were completed by the National Toxicology Program using the dietary route of administration. There was no evidence of carcinogenicity in mice administered approximately 270 mg/kg/day (131 times the human daily dose (HDD) of 10 mg/60 kg/day based on body surface area) or rats administered approximately 50 mg/kg/day (48 times the HDD). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>: Phenylephrine hydrochloride tested negative in the in vitro bacterial reverse mutation assay (<content styleCode="italics">S. typhimurium </content>strains TA98, TA100, TA1535 and TA1537), the in vitro chromosomal aberrations assay, the in vitro sister chromatid exchange assay, and the in vivo rat micronucleus assay. Positive results were reported in only one of two replicates of the in vitro mouse lymphoma assay. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>: Phenylephrine did not impair mating, fertility, or reproductive outcome in normotensive male rats treated with 3 mg/kg/day phenylephrine via continuous intravenous infusion over 1 hour (2.9 times the HDD) for 28 days prior to mating and for a minimum of 63 days prior to sacrifice and female rats treated with the same dosing regimen for 14 days prior to mating and through Gestation Day 6. This dose was associated with increased mortality in both male and female rats and decreased body weight gain in treated males. There were decreased caudal sperm density and increased abnormal sperm reported in males treated with 3 mg/kg/day phenylephrine (2.9 times the HDD). </paragraph>
                     </text>
                     <effectiveTime value="20210323"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID181">
               <id root="3f21950d-2fa2-4536-897f-ecbd776c2c5b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID182">The evidence for the efficacy of phenylephrine hydrochloride injection, is derived from studies of phenylephrine hydrochloride in the published literature. The literature support includes 16 studies evaluating the use of intravenous phenylephrine to treat hypotension during anesthesia. The 16 studies include 9 studies where phenylephrine was used in low-risk (ASA 1 and 2) pregnant women undergoing neuraxial anesthesia during Cesarean delivery, 6 studies in non-obstetric surgery under general anesthesia, and 1 study in non-obstetric surgery under combined general and neuraxial anesthesia. Phenylephrine has been shown to raise systolic and mean blood pressure when administered either as a bolus dose or by continuous infusion following the development of hypotension during anesthesia.</paragraph>
               </text>
               <effectiveTime value="20210323"/>
            </section>
         </component>
         <component>
            <section ID="ID183">
               <id root="99f98d44-629b-4b87-bf3a-876258b4fd5d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID184">Phenylephrine hydrochloride injection USP, 500 mcg/5 mL (100 mcg/mL) for intravenous use, is a clear colorless solution, essentially free from visible extraneous matter available in a clear glass ampule with white snap off and blue band and is supplied as follows: </paragraph>
                  <table ID="ID185" width="472" styleCode="Noautorules">
                     <caption/>
                     <col width="179"/>
                     <col width="113"/>
                     <col width="180"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> NDC No.</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Strength</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> How Supplied</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> NDC 70069-591-10<br/> Pack of 10 '5 mL Single-Dose ampules'<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 500 mcg/5 mL<br/> (100 mcg/mL)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 ampules per carton<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID186">Store phenylephrine hydrochloride injection USP, 500 mcg/5 mL (100 mcg/mL), at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>Protect from light.</paragraph>
                  <paragraph>Discard any unused portion. </paragraph>
               </text>
               <effectiveTime value="20250305"/>
            </section>
         </component>
         <component>
            <section ID="ID187">
               <id root="3c3eb910-5c52-4a7b-ba7c-b667058b87ee"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID188">If applicable, inform patient, family member, or caregiver that certain medical conditions and medications might influence how phenylephrine hydrochloride injection works. </paragraph>
               </text>
               <effectiveTime value="20210323"/>
            </section>
         </component>
         <component>
            <section ID="ID189">
               <id root="7d039604-7c74-44be-b499-71045f61b4a8"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID190">
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>Somerset Therapeutics, LLC</paragraph>
                  <paragraph>Somerset, NJ 08873</paragraph>
                  <paragraph>Made in India</paragraph>
                  <paragraph>Code No.: KR/DRUGS/KTK/28/289/97</paragraph>
                  <paragraph>1201104</paragraph>
                  <paragraph>ST-PHI11/P/00</paragraph>
               </text>
               <effectiveTime value="20250217"/>
            </section>
         </component>
         <component>
            <section ID="ID191">
               <id root="fbaff24b-cd2f-4446-8cea-b244c11c45a4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID192">Container Label</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID194">Carton Label</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250217"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Container</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="5bc23817-cddb-4448-bbf3-969db4cee912-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="5bc23817-cddb-4448-bbf3-969db4cee912-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>